Skip to Content

Posts tagged with "Drug Industry History"

  • Drug Assays

    Software Eats the World, But Biology Eats It

    I can strongly recommend this Bruce Booth post at LifeSciVC on computational models in drug discovery. He’s referencing Marc Andreessen’s famous “Why Software Is Eating the World” essay when he titles his “Four Decades of Hacking Biotech and Yet Biology Still Consumes Everything”. To tell you about where Bruce i… Read More
  • Business and Markets

    Bill Ackman, Pompey, and You

    It’s been about a year since Valeant Pharmaceuticals fell apart into a pile of smoldering rubble. As that link details, its biggest investor and biggest fan, Bill Ackman, was at that point down several billion dollars on the investment, and things did not get any better. His fund sold out of its Valeant position last… Read More
  • Cardiovascular Disease

    The Genomics Revolution Shows Up Late, But Shows Up

    Robert Plenge has an excellent overview of the PCSK9 story up on his site; I recommend it. His take may sound different from mine at first, but I think we’re actually in agreement on a lot of important points. I said that “PCSK9 is about as compelling a story as we’re likely to see in… Read More
  • Cardiovascular Disease

    What PCSK9 Is Telling Us About Drug Discovery

    Friday’s news about the real-world effects of PCSK9 drugs continue to reverberate. It’s worth going into the topic again, but from a wider view of genomics-driven medicine, because this is currently one of the biggest strategies for drug discovery in the industry. The reasoning behind this is pretty compelling. If you comb through the h… Read More
  • Business and Markets

    The Hollywood Analogy

    Yesterday’s drug-research-is-hard screed brought a lot of responses, and I wanted to address some particular points that came up. On Twitter, Alex Tabarrok of Marginal Revolution advanced the Hollywood Analogy. I’ve used this one myself; it leads off a talk that I put together a few years ago. The model for a movie studio is… Read More
  • Clinical Trials

    I Do Hate To Tell You This, But. . .

    The timing of this report from the FDA is surely no accident, but it’s always a good time to think about this: the great majority of all drugs that enter clinical trials fail. They fail because they don’t do anyone any good, or because what good they might do is outweighed by some serious and… Read More
  • Business and Markets

    Out of Ideas?

    The Wall Street Journal came out with a series of articles on innovation in the US, and the biopharma industry features quite a bit in them. The lead one is an overview, with the theme of “The US economy’s hidden problem is that we’re out of big ideas”, and there’s another one specifically on Sanofi… Read More
  • Business and Markets

    Productivity Over the Years

    The last couple of years have been very good for the number of drug approvals, reversing a rather worrying trend. But are these data points themselves enough to qualify as a reversal? That’s what John Carroll is asking here, pointing out that even the traditional end-of-the-year flurry of approvals doesn’t look likely to rescue the num… Read More
  • Business and Markets

    Pfizer Says They Won’t Break Up

    Pfizer has been mulling over the idea of turning into at least two Pfizers for a long time now, but they’re out with an announcement this morning that they’ve decided that their current structure is the one that will help them be the best Pfizer that they can be. That’s going to disappoint a lot of… Read More
  • Drug Assays

    A Quick Survey of the Landscape

    I think, at this point in the history of medicinal chemistry, that we’re now trying to define just what the limits of med-chem might be. By that, I mean small molecules, as opposed to biologics. The early days of the field were naturally a lot more wide open, since there were so many targets that… Read More
...456...